logo-loader
viewMarrone Bio Innovations

Marrone Bio study: MBI-branded biopesticides produce fewer greenhouse gas emissions than traditional pesticides

The study found on average, switching to MBI biopesticides would likely result in net reductions of greenhouse gas emissions of between 69% and 91%

Field with trees and mountains in the background
Marrone Bio holds more than 400 issued and pending patents and has brought six EPA-registered biological product lines and one biostimulant to market

Marrone Bio Innovations Inc (NASDAQ:MBII) has released a study showing a significant reduction in greenhouse gas emissions when utilizing its biopesticides compared with using conventional chemical pesticides. 

The study, done in cooperation with the UC-Davis Graduate School of Management, suggested that switching from conventional products to MBI biopesticides would, on average, likely result in net reductions of greenhouse gas emissions between 69% and 91%, or between 39 and 46 kilograms of CO2 equivalents per acre per year. 

“Our study results underscore how MBI’s products can become an integral part of our customers’ commitment to sustainable agriculture in their pest management and plant health choices,” CEO Pam Marrone said in a statement. “Using our solutions positively affects several emission and climate change factors, helping to create a more sustainable world.”

READ: Marrone Bio Innovations gets California Pesticide regulator approval for new bacteria strain

To measure greenhouse effects, the company said it conducted an inventory analysis on company-wide emissions by source, facility and activity, based on wastewater discharge, water consumption, irrigation water use, electricity use and fuel combustion.

The findings will serve as the foundation for an upcoming Environmental, Social and Governance (ESG) report.

“Companies are increasingly integrating non-financial ESG and sustainability criteria into their corporate reporting, and this trend aligns perfectly with our mission to create a more sustainable world with our innovative biological products,” Marrone said. “This new study on the effects of our product portfolio and our company operations on greenhouse gas emissions represents the first step towards a comprehensive report on our sustainability goals and metrics.”

Founded in 2006 in Davis, California, Marrone Bio holds more than 400 issued and pending patents and has brought six US Environmental Protection Agency-registered biological product lines and one biostimulant to market. Its suite of biologicals includes a bevy of bacteria strains and plant extracts that fight pests, control plant diseases and reduce stress from sun and water.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Marrone Bio Innovations

Price: 1.24 USD

NASDAQ:MBII
Market: NASDAQ
Market Cap: $172.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Marrone Bio Innovations named herein, including the promotion by the Company of Marrone Bio Innovations in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Marrone Bio Innovations receives approval from EPA for...

Marrone Bio Innovations (NASDAQ: MBII) CEO and Founder Dr Pam Marrone joined Steve Darling from Proactive Vancouver on Skype with news that two of its biofungicide products Stargus and Regalia have been approved by the U.S. Environmental Protection Agency for indoor and outdoor use on hemp...

on 01/07/2020

2 min read